Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  BioPorto A/S    BIOPOR   DK0011048619

 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
07/19/2017 07/20/2017 07/21/2017 07/24/2017 07/25/2017 Date
2.68(c) 2.66(c) 2.65(c) 2.63(c) 2.63(c) Last
79 411 83 554 175 892 156 548 232 493 Volume
+0.37% -0.75% -0.38% -0.75% 0.00% Change
More quotes
Company
BioPorto A/S is an in-vitro diagnostics company.It provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies.The company focuses on the diagnosis of obesity, diabetes, primary immune deficiency, and kidney injury.Its products include The NGAL... 
Sector
Pharmaceuticals
Calendar
08/10Earnings Release
More about the company
Latest news on BIOPORTO A/S
07/14 BIOPORTO A/S : Strong data from previous NGAL study provides the basis for new p..
06/12 BIOPORTO A/S : Diagnostics exhibits at the 35th Vicenza Course on AKI & CRRT fro..
06/07 NGAL DEMONSTRATES POSITIVE ECONOMIC : Greatly Reduces Costs Associated With Dia..
06/07 NGAL DEMONSTRATES POSITIVE ECONOMIC : Greatly Reduces Costs Associated With Dia..
05/04 BIOPORTO A/S : Interim report, first quarter of 2017
05/01 BIOPORTO A/S : Invitation to investor meeting in Århus
04/21 BIOPORTO A/S : Annual General Meeting
04/13 BIOPORTO A/S : First patient recruited for The NGAL Test clinical study in the U..
04/12 BIOPORTO A/S : First patient recruited for The NGAL Test™ clinical study i..
04/03 BIOPORTO A/S : Grant of Warrants to Employees and adjustment of EBIT forecast fo..
More news
Sector news : Diagnostic & Testing Substances Manufacturers
07/25DJGlaxoSmithKline Names Former Wal-Mart Executive as Chief Digital and Technolo..
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/25DJABBVIE : Jury Backs AbbVie Payment -- WSJ
07/25DJSamsung Enters U.S. Drug Market -- WSJ
07/24DJABBVIE : Ordered to Pay $150 Million in AndroGel Lawsuit
More sector news : Diagnostic & Testing Substances Manufacturers
Latest Tweets
04/12BioPorto Release: First Patient Recruited For The NGAL Test Clinical Study In.. 
04/12BioPorto A/S : First patient recruited for The NGAL Test™ clinical .. 
01/30BioPorto A/S: BioPorto completes pre-submission discussions with the FDA #Fin.. 
2016BioPorto A/S: BioPorto expands its NGAL related patent portfolio #Finanzierun.. 
More tweets
Qtime:2
Chart BIOPORTO A/S
Duration : Period :
BioPorto A/S Technical Analysis Chart | BIOPOR | DK0011048619 | 4-Traders
Technical analysis trends BIOPORTO A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Managers
NameTitle
Peter Mørch Eriksen CEO & Investor Relations Contact
Thomas Magnussen Chairman
Jan Kuhlmann Andersen Chief Operating Officer
Jakob Brix Christensen Chief Financial Officer
Torben A. Nielsen Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
BIOPORTO A/S26.19%0
JOHNSON & JOHNSON15.45%358 307
ROCHE HOLDING LTD.4.90%221 333
NOVARTIS8.37%220 169
PFIZER2.59%198 425
MERCK AND COMPANY6.29%171 139